BRIUMVI Drives TG Therapeutics Revenue to New Highs, 2026 Guidance Rises on U.S. and Global Momentum

Total Revenue Nearly Doubles, Powered by BRIUMVI's 92% Annual Growth

TG Therapeutics (NASDAQ:TGTX) capped off 2025 with stellar results as BRIUMVI, its flagship monoclonal antibody for relapsing forms of multiple sclerosis (RMS), fueled robust financial performance and drove strategic expansion globally. Full year 2025 net product revenue skyrocketed to $606.93 million, up from $313.73 million in 2024—a jump of 92%. The company’s total revenue for the year reached $616.29 million, almost doubling the prior year’s $329.00 million. BRIUMVI’s success also powered a sharp rebound in net income, with $447.18 million reported for 2025, largely due to a one-time tax benefit.

2026 Outlook: Upbeat Guidance and Sharpened Focus on BRIUMVI Expansion

Looking ahead, TG Therapeutics is forecasting global revenue of $875–900 million for 2026, with U.S. BRIUMVI net product revenue targeted at $825–850 million. The company also expects first-quarter 2026 BRIUMVI revenue in the U.S. to reach $185–190 million. This optimism is underpinned by continued growth in adoption and broader international approvals—the drug is now available across the EU, UK, Switzerland, Australia, Kuwait, and UAE through the company’s partner, Neuraxpharm.

Clinical Pipeline Progress: Multiple Milestones on Deck

Beneath these headline numbers, the BRIUMVI brand continues to strengthen its clinical and commercial profile. The company completed patient enrollment for the ENHANCE trial—evaluating an improved, consolidated dosing regimen—and achieved roughly 75% enrollment in the pivotal Phase 3 program for subcutaneous ublituximab. Mid-year 2026 will bring pivotal ENHANCE topline data, with additional readouts and an expanded clinical pipeline (including azer-cel for progressive MS and autoimmune diseases) coming later in the year and into early 2027.

Share Buyback Program Highlights Optimism

Further signaling confidence in its financial future, TG Therapeutics completed a $100 million share repurchase in Q3 2025, averaging $28.55 per share for roughly 3.5 million shares. A new $100 million buyback authorization is now in place, demonstrating financial discipline and a focus on shareholder value.

BRIUMVI’s Differentiation and Growing Real-World Impact

BRIUMVI’s strong performance is rooted in robust efficacy, tolerability, and a growing body of real-world evidence. Recent data from a six-year open-label extension of pivotal trials showed nearly 90% of RMS patients remained free from 24-week confirmed disability progression. Real-world studies in the ENABLE trial echoed these positive outcomes, reinforcing BRIUMVI’s position among leading MS therapies and supporting expanding physician adoption.

Risks and Considerations: Safety, Competition, and Execution

While momentum is strong, TG Therapeutics faces ongoing safety monitoring (including risks of infusion reactions and infections highlighted in the label), active competition in the RMS space, and the need to sustain commercial execution across a rapidly evolving marketplace. Clinical trial progress, continued global expansion, and payer coverage will all remain critical variables in the company’s bullish scenario for 2026.

Key Financials Snapshot

Bottom Line: BRIUMVI Traction and Robust Financial Outlook Signal Strong Momentum for TG Therapeutics

With BRIUMVI continuing to gain ground globally and a ramped-up clinical development pipeline, TG Therapeutics has set the stage for another year of substantial growth and value creation. Investors and industry watchers will be focused on 2026 clinical milestones, real-world market share gains, and management’s ability to deliver on its bullish financial guidance.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI